LEXXW - Lexaria Enters Investor Relations Agreement
(TheNewswire)
Kelowna, British Columbia – TheNewswire - February 16, 2021 – Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (CSE:LXX) (CNSX:LXX.CN) (the “Company” or“Lexaria”), a global innovator in drug delivery platforms,announces its engagement of Accretive Capital LLC, a Delaware limitedliability company doing business as Benzinga, to provide investorrelations services (“ IRServices ”) to the Company.
The Company has agreed to pay Benzinga US$16,000 forthe provision of its IR Services over a one year term. The IRServices shall include the participation of the Company in threeBenzinga conferences during the year term, along with marketing theCompany on Benzinga’s virual event platform, SmallCap website, innewsletters, social media, video presentation and via editorialcoverage.
Lexaria Bioscience Corp.’s proprietary drug deliverytechnology, DehydraTECH™, improves the way active pharmaceuticalingredients (APIs) enter the bloodstream by promoting healthier oralingestion methods and increasing the effectiveness of fat-solubleactive molecules, thereby lowering overall dosing. The Company’stechnology can be applied to many different ingestible productformats, including foods, beverages, oral suspensions, tablets, andcapsules. DehydraTECH has repeatedly demonstrated since 2016 withcannabinoids and nicotine the ability to increase bio-absorption by upto 5-10x, reduce time of onset from 1 - 2 hours to minutes, and maskunwanted tastes; and is planned to be further evaluated for orallyadministered bioactive molecules, including anti-virals, cannabinoids,vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), andnicotine. Lexaria has licensed DehydraTECH to multiple companiesincluding a world-leading tobacco producer for the development ofsmokeless, oral-based nicotine products and for use in industries thatproduce cannabinoid beverages, edibles, and oral products. Lexariaoperates a licensed in-house research laboratory and holds a robustintellectual property portfolio with 18 patents granted andapproximately 60 patents pending worldwide. For more information,please visit www.lexariabioscience.com .
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press releaseincludes forward-looking statements. Statements as such term isdefined under applicable securities laws. These statements may beidentified by words such as "anticipate," "if,""believe," "plan," "estimate,""expect," "intend," "may,""could," "should," "will," and othersimilar expressions. Such forward-looking statements in this pressrelease include, but are not limited to, statements by the companyrelating the Company’s ability to carry out research initiatives,receive regulatory approvals or grants or experience positive effectsor results from any research or study. Such forward-looking statementsare estimates reflecting the Company's best judgment based uponcurrent information and involve a number of risks and uncertainties,and there can be no assurance that the Company will actually achievethe plans, intentions, or expectations disclosed in theseforward-looking statements. As such, you should not place unduereliance on these forward-looking statements. Factors which could cause actualresults to differ materially from those estimated by the Companyinclude, but are not limited to, government regulation and regulatory approvals, managing and maintaininggrowth, the effect of adverse publicity, litigation, competition,scientific discovery, the patent application and approval process,potential adverse effects arising from the testing or use of productsutilizing the DehydraTECH technology, the Company’s ability tomaintain existing collaborations and realize the benefits thereof,delays or cancellations of planned R&D that could occur related topandemics, and other factors which may be identified from time to timein the Company's public announcements and periodic filings with the USSecurities and Exchange Commission on EDGAR. There is no assurancethat any of Lexaria’s postulated uses, benefits, or advantages forthe patented and patent-pending technology will in fact be realized inany manner or in any part. No statement herein has been evaluated bythe Food and Drug Administration (FDA). Lexaria-associated productsare not intended to diagnose, treat, cure or prevent any disease. Anyforward-looking statements contained in this release speak only as ofthe date hereof, and the Company expressly disclaims any obligation toupdate any forward-looking statements contained herein, whether as aresult of any new information, future events, changed circumstances orotherwise, except as otherwise required by law.
TheCSE has not reviewed and does not accept responsibility for theadequacy or accuracy of this release.
INVESTOR CONTACT:
Copyright (c) 2021 TheNewswire - All rights reserved.